Fig. 1
From: Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China
Cumulative Number of Cell Therapy Products Approved for Marketing by the NMPA, FDA, EMA and PMDA (2010–2024). Abbreviations: FDA, Food and Drug Administration; EMA, European Medicines Agency; PMDA, Pharmaceuticals and Medical Devices Agency; NMPA, National Medical Products Administration. IC, Immune Cell; SC, Stem Cell; OSC, Other Somatic Cell. Note: The cut-off date was August 1, 2024